Sophie Kervyn

Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (<scp>SV</scp>2A) ligand with preclinical evidence of high brain permeability and fast onset of action

Jean‐Marie Nicolas, Jonas Hannestad, Daniel Holden et al. · Epilepsia · 2015 · 159 citations · Full text

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development

Sally Robinson, Jean‐Luc Delongeas, Elizabeth Donald et al. · Regulatory Toxicology and Pharmacology · 2007 · 104 citations

Drug Safety, Regulatory Requirement, Medicine +10

A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studies

Kathryn Chapman, Fiona Sewell, Linda Allais et al. · Regulatory Toxicology and Pharmacology · 2013 · 70 citations · Full text

A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers

Sjoerd J. Finnema, Samantha Rossano, Mika Naganawa et al. · Epilepsia · 2019 · 60 citations · Full text

Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative

Jamie K. DaSilva, Laura Breidenbach, Tracy Deats et al. · Journal of Pharmacological and Toxicological Methods · 2020 · 11 citations

Neuropsychology, Nonclinical Species Sensitivity, Behavioral Neuroscience +8